Sable Therapeutics, a portfolio company of Turret Capital Management, announces licensing agreement for Greater China NEW YORK, April 25, 2023 /PRNewswire/ — Sable Therapeutics, an early stage biotechnology company developing novel therapies for fat reduction, today announced that it…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.